Search

Your search keyword '"Yokota, Naoto"' showing total 10 results
Start Over Author "Yokota, Naoto" Publication Year Range Last 3 years
10 results on '"Yokota, Naoto"'

1. C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled Study

Author

Kojima, Sunao, Uchiyama, Kazuaki, Yokota, Naoto, Tokutake, Eiichi, Wakasa, Yutaka, Hiramitsu, Shinya, Waki, Masako, Jinnouchi, Hideaki, Kakuda, Hirokazu, Hayashi, Takahiro, Kawai, Naoki, Sugawara, Masahiro, Mori, Hisao, Tsujita, Kenichi, Matsui, Kunihiko, Hisatome, Ichiro, Ohya, Yusuke, Kimura, Kazuo, Saito, Yoshihiko, and Ogawa, Hisao

Published
2023
Full Text
View/download PDF

3. Impacts of Febuxostat on Cerebral and Cardiovascular Events in Elderly Patients with Hyperuricemia: Post Hoc Analysis of a Randomized Controlled Trial.

Author

Sugawara, Masahiro, Kojima, Sunao, Hisatome, Ichiro, Matsui, Kunihiko, Uchiyama, Kazuaki, Yokota, Naoto, Tokutake, Eiichi, Wakasa, Yutaka, Hiramitsu, Shinya, Waki, Masako, Jinnouchi, Hideaki, Kakuda, Hirokazu, Hayashi, Takahiro, Kawai, Naoki, Mori, Hisao, Tsujita, Kenichi, Ohya, Yusuke, Kimura, Kazuo, Saito, Yoshihiko, and Ogawa, Hisao

Subjects
OLDER patients, FEBUXOSTAT, RANDOMIZED controlled trials, HYPERURICEMIA, AGE groups, CEREBRAL malaria
Abstract

A recent meta‐analysis found no benefit of uric acid‐lowering therapy including febuxostat on death, cardiovascular events, or renal impairment. However, there may be populations that benefit from febuxostat in reducing mortality and cerebral and cardiovascular events. The aim of the present study was to examine the clinical benefit of febuxostat in elderly patients stratified by age using Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy (FREED) data. FREED was a randomized study involving patients aged 65 years or older with hyperuricemia and risk factors for cerebral, cardiovascular, or renal diseases. A total of 1,070 patients were included in this post hoc analysis, divided into 2 age groups: 65–74 years and ≥ 75 years. Patients were randomized into febuxostat and non‐febuxostat groups, with uric acid levels monitored for 36 months. The primary composite end point included cerebral, cardiovascular, and renal events. In patients aged between 65 and 74 years, febuxostat significantly reduced the risk of future cerebral and cardiorenovascular events. However, no effects of febuxostat were found in the older population aged ≥ 75 years. Heterogeneity in potential interactions between the age and febuxostat treatment was particularly observed in non‐fatal cerebral and cardiovascular events and all‐cause death. Patients aged ≥ 75 years exhibited more pre‐existing factors associated with cerebral and cardiorenovascular events than those aged 65–74 years. The effectiveness of febuxostat varies by age group, with potential benefits for patients aged 65–74 years. The effects of febuxostat are complex and it is important to consider patient characteristics in its clinical use. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.

Author

Kohagura, Kentaro, Kojima, Sunao, Uchiyama, Kazuaki, Yokota, Naoto, Tokutake, Eiichi, Wakasa, Yutaka, Hiramitsu, Shinya, Waki, Masako, Jinnouchi, Hideaki, Kakuda, Hirokazu, Hayashi, Takahiro, Kawai, Naoki, Sugawara, Masahiro, Mori, Hisao, Tsujita, Kenichi, Matsui, Kunihiko, Hisatome, Ichiro, Ohya, Yusuke, Kimura, Kazuo, and Saito, Yoshihiko

Published
2023
Full Text
View/download PDF

7. C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled Study

Author

Kojima, Sunao, primary, Uchiyama, Kazuaki, additional, Yokota, Naoto, additional, Tokutake, Eiichi, additional, Wakasa, Yutaka, additional, Hiramitsu, Shinya, additional, Waki, Masako, additional, Jinnouchi, Hideaki, additional, Kakuda, Hirokazu, additional, Hayashi, Takahiro, additional, Kawai, Naoki, additional, Sugawara, Masahiro, additional, Mori, Hisao, additional, Tsujita, Kenichi, additional, Matsui, Kunihiko, additional, Hisatome, Ichiro, additional, Ohya, Yusuke, additional, Kimura, Kazuo, additional, Saito, Yoshihiko, additional, and Ogawa, Hisao, additional

Published
2022
Full Text
View/download PDF

8. Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease

Author

Konishi, Masaaki, primary, Kojima, Sunao, additional, Uchiyama, Kazuaki, additional, Yokota, Naoto, additional, Tokutake, Eiichi, additional, Wakasa, Yutaka, additional, Hiramitsu, Shinya, additional, Waki, Masako, additional, Jinnouchi, Hideaki, additional, Kakuda, Hirokazu, additional, Hayashi, Takahiro, additional, Kawai, Naoki, additional, Sugawara, Masahiro, additional, Mori, Hisao, additional, Tsujita, Kenichi, additional, Matsui, Kunihiko, additional, Hisatome, Ichiro, additional, Ohya, Yusuke, additional, Kimura, Kazuo, additional, Saito, Yoshihiko, additional, and Ogawa, Hisao, additional

Published
2022
Full Text
View/download PDF

9. Cardiovascular Prognosis in Drug-Resistant Hypertension Stratified by 24-Hour Ambulatory Blood Pressure: The JAMP Study

Author

Kario, Kazuomi, primary, Hoshide, Satoshi, additional, Narita, Keisuke, additional, Okawara, Yukie, additional, Kanegae, Hiroshi, additional, Aoki, Kenji, additional, Kihara, Hajime, additional, Koga, Toshiro, additional, Nakata, Tomoaki, additional, Oku, Kenji, additional, Matsuoka, Yasufumi, additional, Omori, Hiroaki, additional, Nishizawa, Masafumi, additional, Tanno, Yasuo, additional, Fukase, Yoko, additional, Omi, Koki, additional, Takahashi, Jun, additional, Mizuno, Hiroyuki, additional, Saito, Michiya, additional, Yatabe, Junichi, additional, Eguchi, Kazuo, additional, Iwashita, Kiyoshi, additional, Kumada, Maki, additional, Oki, Gaku, additional, Kabutoya, Tomoyuki, additional, Hojo, Yukihiro, additional, Ichida, Masaru, additional, Ishikawa, Shizukiyo, additional, Komori, Takahiro, additional, Matsui, Yoshio, additional, Matsumoto, Masatoshi, additional, Nagasaka, Shoichiro, additional, Nakano, Masahiro, additional, Nishimura, Yoshioki, additional, Okada, Kenta, additional, Shimada, Kazuyuki, additional, Shimpo, Masahisa, additional, Takahashi, Nozomu, additional, Uno, Hideyuki, additional, Ishikawa, Joji, additional, Kuroda, Toshio, additional, Hirahara, Nobutsune, additional, Kemi, Yuta, additional, Yoshioka, Hisashi, additional, Hoshi, Sakuo, additional, Mizuno, Atsuhi, additional, Ohno, Kunihiko, additional, Okazaki, Osamu, additional, Saito, Tsunehiro, additional, Tanaka, Tetsu, additional, Yamashiro, Kazuo, additional, Yamauchi, Tatsuyuki, additional, Yo, Shisei, additional, Yomogita, Shigeru, additional, Hikita, Sayaka, additional, Kawase, Yasuhiro, additional, Nojiri, Yoshifumi, additional, Sato, Yukihiro, additional, Uchiba, Kiyoshi, additional, Ishiguro, Motoyuki, additional, Taguchi, Atsushi, additional, Iida, Kazumasa, additional, Takemoto, Tatsuya, additional, Tone, Katsuyuki, additional, Abe, Hideyasu, additional, Abe, Yasuhisa, additional, Hasegawa, Masami, additional, Katsuya, Tomohiro, additional, Okada, Yoshiharu, additional, Tanaka, Shinichiro, additional, Tanke, Genyo, additional, Takami, Takeshi, additional, Michiura, Jun, additional, Shiotani, Masahiko, additional, Aoki, Tomohiro, additional, Ogura, Koichi, additional, Kawamura, Yuzuru, additional, Nakanishi, Shigekiyo, additional, Sasaki, Nobuo, additional, Takahashi, Toshiyuki, additional, Fujii, Akihisa, additional, Tanaka, Eiichiro, additional, Katayama, Hiroyuki, additional, Fukutomi, Motoki, additional, Miyoshi, Kosuke, additional, Naito, Hiroaki, additional, Yokota, Sawa, additional, Nakamura, Kazumasa, additional, Yokota, Tetsu, additional, Takasugi, Shinsuke, additional, Fujita, Shuichiro, additional, Fujita, Yumiko, additional, Kaneko, Hitoshi, additional, Fujiwara, Takeshi, additional, Kitamura, Wataru, additional, Anan, Yuhei, additional, Deguchi, Tomohiro, additional, Imaizumi, Yuki, additional, Miyagi, Jun, additional, Tsuji, Takahiro, additional, Uchiwa, Yasuhiro, additional, Ueda, Shin, additional, Yamaguchi, Takeya, additional, Yoshida, Tetsuro, additional, Yoshinaga, Ryo, additional, Maeda, Kosuke, additional, Kunitomo, Kotaro, additional, Soda, Kyousei, additional, Baba, Hirotoshi, additional, Yonezu, Keisuke, additional, Hino, Akihiro, additional, Miura, Genta, additional, Nakamura, Tomoko, additional, Kuroki, Munetoshi, additional, Omori, Fumihiko, additional, Hidaka, Toshiaki, additional, Hidaka, Takanori, additional, Yano, Yuichiro, additional, Kanemaru, Yoshimasa, additional, Kitani, Michitaka, additional, Koga, Masahiro, additional, Kubo, Hirohide, additional, Kuwabara, Masachika, additional, Miyata, Junichi, additional, Nagata, Masahiko, additional, Sasaki, Koji, additional, Tamaki, Noboru, additional, Tasaka, Hiroyasu, additional, Yokota, Naoto, additional, Miyata, Takahiro, additional, Katsuren, Eiyu, additional, Kudeken, Norifumi, additional, and Yagi, Noriharu, additional

Published
2021
Full Text
View/download PDF

10. Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trial.

Author

Kojima, Sunao, Uchiyama, Kazuaki, Yokota, Naoto, Tokutake, Eiichi, Wakasa, Yutaka, Hiramitsu, Shinya, Waki, Masako, Jinnouchi, Hideaki, Kakuda, Hirokazu, Hayashi, Takahiro, Kawai, Naoki, Sugawara, Masahiro, Mori, Hisao, Tsujita, Kenichi, Matsui, Kunihiko, Hisatome, Ichiro, Ohya, Yusuke, Kimura, Kazuo, Saito, Yoshihiko, and Ogawa, Hisao

Subjects
KIDNEY disease risk factors, HYPERURICEMIA, CARDIOVASCULAR diseases risk factors, STATISTICS, LOG-rank test, HEALTH outcome assessment, COMPARATIVE studies, URIC acid, DATA analysis, THIAZOLES
Abstract

Objectives Hyperuricaemia is recognized as an independent risk marker for cardiovascular and renal diseases. However, uric acid is a powerful free-radical scavenger, and the optimal level of serum uric acid (SUA) determining outcomes is unknown. This study explored whether interventional treatments for excessive SUA reduction were harmful and what constituted the optimal lowering of SUA levels for the prevention of events in patients with asymptomatic hyperuricaemia. Methods This was a post hoc analysis of a randomized trial (Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy [FREED]) in which 1070 older patients with asymptomatic hyperuricaemia were enrolled and allocated to febuxostat (n  = 537) or non-febuxostat treatment group (n  = 533). We assessed the relationship between the endpoint (withdrawal or study completion) SUA levels and clinical outcomes. Primary endpoint was defined as a composite of all-cause mortality, cerebral and cardiorenovascular events. Results In the febuxostat group, patients achieving SUA levels ≤4 mg/dl (hazard ratio: 2.01 [95% CI: 1.05, 3.87]), >4 to ≤5 mg/dl (2.12 [1.07, 4.20], >6 to ≤7 mg/dl (2.42 [1.05, 5.60]), and >7 mg/dl (4.73 [2.13, 10.5]) had significantly higher risks for a primary composite event than those achieving SUA levels >5 to ≤6 mg/dl (P = 0.003 [log-rank test]). This J-shaped relationship applied to patients with renal impairment (P  = 0.007 [Gray's test]) and was not significant in the non-febuxostat treatment group (P  = 0.212 [log-rank test]). Conclusion Optimal SUA level by febuxostat treatment is 5–6 mg/dl for reducing all-cause mortality, cerebral, cardiovascular and renal events. Excessive SUA reduction may be harmful in older hyperuricaemic populations. Trial Registration ClinicalTrial.gov , https://clinicaltrials.gov , NCT01984749 [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results